The relationship between overexpression of glial cell-derived neurotrophic factor and its RET receptor with progression and prognosis of human pancreatic cancer
- PMID: 18652760
- DOI: 10.1177/147323000803600406
The relationship between overexpression of glial cell-derived neurotrophic factor and its RET receptor with progression and prognosis of human pancreatic cancer
Abstract
We used immunohistochemical staining to assess protein over-expression of glial cell-derived neurotrophic factor (GDNF) and its RET receptor tyrosine kinase in patients with pancreatic cancer and benign pancreatic neoplasm, and assessed correlations with clinicopathological features and prognosis. Surgically resected pancreatic cancer patients (40/58, 68.9%) showed positive GDNF immunostaining, a significantly higher frequency than in patients with benign pancreatic tumour (3/11, 27.3%). Intrapancreatic neural invasion by cancer cells was significantly related to over-expression of GDNF. Strongly positive expression of GDNF was significantly more frequent than lesser grades of expression in patients with severe back pain before and 12 months after surgery. Expression of RET was significantly related to lymphatic invasion, survival rate after tumour resection and degree of tumour cell differentiation. We conclude that GDNF may be important in pancreatic cancer proliferation and metastasis, especially in patients with perineural invasion. Strongly positive expression of GDNF may be an indication for early intensified radiotherapy. RET expression in pancreatic cancer tissues may be a useful prognostic marker.
Similar articles
-
Expression of glial cell line-derived neurotrophic factor family members and their receptors in pancreatic cancers.Surgery. 2005 Oct;138(4):788-94. doi: 10.1016/j.surg.2005.07.007. Surgery. 2005. PMID: 16269310
-
The G691S RET polymorphism increases glial cell line-derived neurotrophic factor-induced pancreatic cancer cell invasion by amplifying mitogen-activated protein kinase signaling.Cancer Res. 2005 Dec 15;65(24):11536-44. doi: 10.1158/0008-5472.CAN-05-2843. Cancer Res. 2005. PMID: 16357163 Clinical Trial.
-
The role of glial cell line-derived neurotrophic factor (GDNF) and integrins for invasion and metastasis in human pancreatic cancer cells.J Surg Oncol. 2005 Jul 1;91(1):77-83. doi: 10.1002/jso.20277. J Surg Oncol. 2005. PMID: 15999351
-
CXCR2 and RET single nucleotide polymorphisms in pancreatic cancer.World J Surg. 2009 Apr;33(4):710-5. doi: 10.1007/s00268-008-9826-z. World J Surg. 2009. PMID: 19057948 Review.
-
GDNF and the RET Receptor in Cancer: New Insights and Therapeutic Potential.Front Physiol. 2019 Jan 7;9:1873. doi: 10.3389/fphys.2018.01873. eCollection 2018. Front Physiol. 2019. PMID: 30666215 Free PMC article. Review.
Cited by
-
Receptor tyrosine kinase gene expression profiling of orbital rhabdomyosarcoma unveils MET as a potential biomarker and therapeutic target.Hum Cell. 2024 Jan;37(1):297-309. doi: 10.1007/s13577-023-00993-5. Epub 2023 Nov 2. Hum Cell. 2024. PMID: 37914903
-
Targeting the RET tyrosine kinase in neuroblastoma: A review and application of a novel selective drug design strategy.Biochem Pharmacol. 2023 Oct;216:115751. doi: 10.1016/j.bcp.2023.115751. Epub 2023 Aug 16. Biochem Pharmacol. 2023. PMID: 37595672 Review.
-
The Role of Neural Signaling in the Pancreatic Cancer Microenvironment.Cancers (Basel). 2022 Aug 31;14(17):4269. doi: 10.3390/cancers14174269. Cancers (Basel). 2022. PMID: 36077804 Free PMC article. Review.
-
An integrative pan cancer analysis of RET aberrations and their potential clinical implications.Sci Rep. 2022 Aug 17;12(1):13913. doi: 10.1038/s41598-022-17791-y. Sci Rep. 2022. PMID: 35978072 Free PMC article.
-
RET signaling pathway and RET inhibitors in human cancer.Front Oncol. 2022 Jul 25;12:932353. doi: 10.3389/fonc.2022.932353. eCollection 2022. Front Oncol. 2022. PMID: 35957881 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
